

- A review of the double-masked, controlled clinical trials with the four fixed-combination products that have published results in the ophthalmic literature - Xalacom[®] (Pfizer, New York, USA), DuoTrav[®] (Alcon, Fort Worth, USA), Ganfort[®] (Allergan, Irvine, USA), and TAF/TIM (Santen Oy, Tampere, Finland) - was performed.
- Focus was on the analysis of mean intraocular pressure (IOP) change at 3 months; regarding safety, the emphasis was on investigating hyperemia and ocular irritation.
- Products yielded a similar reduction in IOP of around 32-36% from an untreated baseline IOP of around 24-29 mmHg.
- The mean IOP at baseline seemed to predominantly explain the magnitude of IOP reduction.
- Least side effects occurred during treatment with TAF/TIM and Xalacom[®]; of these two, TAF/TIM is preservative free.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Santen Oy, Tampere, Finland. Editorial assistance in the preparation of this manuscript was provided by Johan Stjernschantz, MD, PhD, Synphora Ab, Sweden. Support for this assistance was funded by Santen Oy. Support for this assistance was funded by Santen Oy. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2014. Creative Commons Attribution Noncommercial License (CC BY-NC).